Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease by Barta, Zsolt et al.
P.O.Box 2345, Beijing 100023,China                                                                                                                                                                 World J Gastroenterol  2003;9(10):2308-2312
Fax: +86-10-85381893                                                                                                                                                                                                                                 World Journal of Gastroenterology
E-mail: wjg@wjgnet.com     www.wjgnet.com                                                                                                                                   Copyright © 2003 by The WJG Press ISSN 1007-9327
• CLINICAL RESEARCH •
Seroreactivity against Saccharomyces cerevisiae in patients with
Crohn’s disease and celiac disease
Zsolt Barta, István Csípõ, Gábor G. Szabó, Gyula Szegedi
Zsolt Barta, István Csípõ, Gábor G. Szabó, Gyula Szegedi, 3rd
Department of Medicine, University of Debrecen, Móricz Zs. Krt.
22. 4004 Debrecen, Hungary
Correspondence to: Zsolt Barta, M.D., 3rd Department of Medicine,
University of Debrecen, Móricz Zs. Krt.22. 4004 Debrecen, Hungary.
mailto:barta@iiibel.dote.hu
Telephone: +36-52-453-337    Fax: +36-52-414-969
Received: 2003-03-12    Accepted: 2003-05-09
Abstract
AIM: To explore whether there was anti-Saccharomyces
cerevisiae antibodies (ASCA) positivity in our patients with
biopsy-confirmed celiac disease.
METHODS: A cohort of patients with inflammatory bowel
diseases (42 patients with Crohn’s disease and 10 patients
with ulcerative colitis) and gluten sensitive enteropathy (16
patients) from Debrecen, Hungary were enrolled in the study.
The diagnosis was made using the formally accepted criteria.
Perinuclear antineutrophil cytoplasmic antibodies (pANCA)
and anti-Saccharomyces cerevisiae antibodies (ASCA),
antiendomysium antibodies (EMA), antigliadin antibodies
(AGA) and anti human tissue transglutaminase antibodies
(tTGA) were investigated.
RESULTS: The results showed that ASCA positivity occurred
not only in Crohn’s disease but also in Celiac disease and in
these cases both the IgG and IgA type antibodies were proved.
CONCLUSION: It is conceivable that ASCA positivity correlates
with the (auto-) immune inflammation of small intestines
and it is a specific marker of Crohn’s disease.
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INTRODUCTION
Gluten-sensitive enteropathy (GSE) or, as it is more commonly
called, celiac disease, is an immune-mediated enteropathic
condition (specified as an autoimmune inflammatory disease
of the small intestine) that is precipitated by the ingestion of
gluten, a component of wheat protein, in genetically susceptible
persons. Exclusion of dietary gluten results in healing of the
mucosa, resolution of the malabsorptive state, and reversal of
most, if not all, effects of celiac disease. GSE commonly
manifests as “silent” celiac disease (i.e., minimal or no
symptoms). Histological examination and serologic tests for
antibodies against endomysium, transglutaminase, and gliadin
identify most patients with the disease[1].
     Crohn’s disease (CD) and ulcerative colitis (UC) are both
classified under the medical rubric of inflammatory bowel
disease (IBD). It is currently accepted that the term “IBD”
does not encompass just two diseases (CD or UC), but rather a
group of diseases, triggered and perpetuated by a variety of
diverse genetic, environmental, and immunologic factors that
share similar clinical manifestations. They cause life-impaired
symptoms, necessitate long-term dependence on powerful
drugs, and often result in debilitating surgery and even death.
Although the etiology of UC and CD remains unclear, in
addition to genetic and other environmental factors (food
allergens, etc.), microorganisms have been discussed as
possibly playing an important role. The gastrointestinal (GI)
tract has direct contact with the environment and therefore
forms a very important protective barrier within the human’s
organism. The gut mucosa has to stop foreign materials, such
as bacteria or antigens, from entering the body and also prevent
excessive loss of “body material” into the lumen. If the mucosal
barrier is broken, an influx of luminal antigens may result in
the perpetuation of intestinal inflammation by chronically
stimulating resident and recruited immunocompetent cells of
the lamina propria. Bacteria present within the intestinal lumen
or in the intestinal wall are important in the development of
mucosal inflammation. Recent reports in the literature do not
suggest that a specific persistent infection causes IBD (i.e. the
repeatedly blamed Mycobacterium paratuberculosis avium),
but indicate that enteric pathogens could cause initial onset of
IBD and are associated with reactivation of quiescent disease.
CD patients may have a heterogeneous serological response
to specific bacteria and bacterial related antigens. The serologic
responses seen in CD patients include antibodies to
Saccharomyces cerevisiae, Mycobacteria, Bacteriodes,
Listeria, and E. coli. Many of the specific organisms have been
proposed to directly or indirectly contribute to the pathogenesis
of CD. Despite their self-limited character, these infections
initiate a cascade of inflammatory events leading to chronic,
relapsing disease in a genetically susceptible host (“hit-and-
run” hypothesis). So, epidemiological and microbiologic
studies suggest that enteropathogenic microorganisms play a
substantial role in the clinical initiation and relapses of IBD.
Thus microbiologic screening might be helpful in patients with
flares of IBD for optimal medical treatment and as many
bacteria cannot be cultured, culture-independent techniques
are expected to be of great help in identifying microorganisms
in IBD. With more comprehensive knowledge of the intestinal
microflora and how the latter interacts with the host’s immune
system, it may be possible to define specific microbial
substances in specific patients that are either present or absent
from the normal flora to cause disease. The diagnoses of CD,
UC and GSE are based on clinical features and the results of
barium X-rays, endoscopy, mucosal biopsy histology, and in
some cases operative findings and resected bowel pathology
and histology. Serologic disease markers are accepted in GSE
but unambiguously in IBD. Serologic tests that could serve as
an adjunct to these invasive and expensive diagnostic studies,
or possibly replace them, would have clinical utility[2-5].
Antibodies have attracted much interest for the study of the
immune response in inflammatory bowel disease (IBD) and
are also used as a tool for phenotyping. Antibodies to baker’s
yeast and brewer’s yeast (anti-Saccharomyces cerevisiae
antibodies or ASCA) directed against cell wall oligomannoside
epitopes have been proposed as a serological marker for CD[6,7].
They have a sensitivity of 60 % and a specificity of 80-95 %
for differentiating CD from controls[8]. One small study also
reported the production of ASCA by a fraction of unaffected
relatives of Crohn’s patients. The role of ASCA’s in CD is
completely unknown, but one hypothesis links them to
increased intestinal permeability. 50-60 % of patients with CD
exhibit an activity-related increase in intestinal permeability,
and this increase might be predictive for relapse. A variable
proportion of healthy first-degree relatives of CD patients also
have abnormal permeability of the small intestine, which lead
some authors to postulate a primary defect of the tight junctions
as etiologic factor in CD. Increased exposure of the epithelium
to common food antigens such as yeasts due to a break in the
epithelial barrier may then result in an antibody response. The
effect of dietary yeast (Saccharomyces cerevisiae) on the
activity of stable CD disease was assessed in patients. The
patients’ mean CD activity index (CDAI) while taking baker’s
yeast was significantly greater than that during yeast exclusion
and patients with elevated yeast antibodies tended to develop
a higher CDAI while receiving baker’s yeast. These results
suggest that dietary yeast may affect the activity of CD[9].
Antinuclear cytoplasmic antibodies (ANCA) with a perinuclear
staining pattern have been proposed as a serologic marker for
UC. pANCA’s were found in 60-70 % of patients with UC.
There is no clear association of pANCA with severity of disease
but it is predictive of pouchitis after restorative proctocolectomy
with ileoanal pouch anastomosis[10]. pANCA’s are also found
in 15-20 % of patients with CD. These patients present diffuse
left-sided colitis with symptoms such as rectal bleeding,
urgency, and mucus discharge and this phenotype is labeled
“UC-like CD”.
     Saccharomyces cerevisiae (SC) is “ubiquitous” yeast and
occurs in diverse places in naturally on plants and in the ground.
Mankind used in the past and use now yeast for making
miscellaneous foods (i.e. beer, bread) so we can come into
contact with it principally with our consumed food products
and beverages. It is generally accepted that SC is not a
pathogen, but it has been suggested that in case of fungemia
with SC (in patients with damaged/defective immune system)
various organs can be affected and injured. The titer of pANCA
does not change with the activity of the disease, does not
depend on the therapy or the surgical intervention and but
persists after resection of the affected part of the bowels.
Similarly, the titer of the ASCA is stable irrespective of the
activity of the disease and the drug-therapy. ASCA titers
correlated with small bowel involvement and occurred
particularly in cases of young adults with CD.
     The aim of the study was to determine the prevalence of
serological markers for GSE and IBD in patients with celiac
disease (16 patients), UC (10 patients) and Crohn’s disease
(42 patients) and to correlate the presence with the
characteristics of these diseases.
MATERIALS AND METHODS
Patients
The entire cohort of patients with IBD (42 patients with CD
and 10 patients with UC) and GSE (16 patients) from Debrecen,
Hungary were enrolled in the study. Adult patients of both
sexes were included. The diagnosis of CD, UC or GSE was
made using the formally accepted criteria. The medical records
for these patients have previously been reviewed by
investigators and abstracted for patient characteristics. The
blood samples for the study were collected between January
2000 and March 2000. Their sera were separated and stored at
-70 . Determination of serum values was performed by
individuals blinded to the clinical data for the patients in our
Regional Immunology Laboratory.
Specific antibody measurement
Gliadin  Glia-test from Diagnosticum Rt.(Budapest, Hungary)
was warmed up to room temperature and the dilution of the
diluents solution and the buffer solution was dispensed. For
the measurement of specific IgG and IgA, the samples were
diluted 1:500 (v/v). Micro standardization strips were incubated
with one hundred microlitres of washing buffer, negative
control, IgA positive control, IgG positive control, and the
samples from the patients, for 30 min at 37 . After the
incubation, the plate was washed three times with a Labsystems
ELISA washer (Beverly, MA). Both of the anti-IgG and anti-
IgA conjugate were diluted 1:200 in diluents solution (100 mL
per well divided). Wells were again incubated for 30 min at
37  and washed three times with two hundred microlitres of
washing buffer. Next step was incubation with 100 mL of TM B
substrate buffer (protected from light) at room temperature
for 30 min. Reaction was stopped with 50 mL 4N sulphuric
acid per well. Optical density (OD) was determined at 450 nm.
All chemical reagents were reagent grade, from Sigma unless
otherwise stated.
Transglutaminase  Greiner plates (N°655180) were incubated
with transglutaminase, dissolved in PBS at 10 mg per milliliters,
50 mL per well, 16 hours at +4 . Binding sites were blocked
by incubating with two hundred microlitres per well of 1 %
(w/v) bovine serum albumin (BSA) in PBS for 2 hours at 37 .
100 mL per well of each sample as incubated at room
temperature for 2 hours. (For the measurement, the serum
samples were diluted 1:100) Anti-human IgA/HRPO
conjugate, diluted 1:4 000 (v/v) in diluents solution (1 % BSA-
PBS) were incubated (100 mL per well) for 1 hour at room
temperature. The color reaction was developed by adding a
solution (containing 12.5 ml citrate-phosphate buffer pH 5.0,
4.25 mg OPD, 5 mL of 30 % H2O2). The enzymatic reaction
was stopped after 15 min with 50 mL per well of 4N H2SO4.
Optical density (OD) was determined at 492 nm. After each
incubation step, wells were washed two times with PBS
containing 0.05 % (v/v) Tween 20 (PBS-T) during 10 minutes.
Each sample was analyzed in duplicate. All chemical reagents
were reagent grade, from Sigma unless otherwise stated.
Endomysium  Indirect immunofluorescent method was
developed in our laboratory. The substrate (umbilical cord)
was incubated in PBS with sera (diluted 1:10 in diluent),
washed twice with PBS for 10 min, then incubated with anti-
human IgA/FITC and IgG/FITC, washed twice with PBS for
10 min. The preparates were coated with a mixture of glycerin/
PBS (1:1) and covered with cover plate. Evaluation was
interpreted with fluorescent microscopy. All chemical reagents
were reagent grade, from Sigma.
ASCA IgG and IgA  Medizym® ASCA IgA is an enzyme
immunoassay for the quantitative determination of IgA
antibodies to Saccharomyces cerevisiae in human serum.
Autoantibodies of the diluted patient samples and calibrators
reacted with mannan (cell surface component of baker’s yeast)
immobilized on the solid phase of a microtiter plate. Following
an incubation period of 60 min at 37 , unbound serum
components are removed by a washing step. The bound
antibodies react specifically with anti-human-IgA-antibodies
conjugated to horseradish peroxidase (HRPO). Within the
incubation period of 30 min at 37 , excessive conjugate was
separated from the solid-phase immune complexes by the
following washing step. Horseradish peroxidase converted the
colorless substrate solution of 3, 3’, 5, 5’-tetramethylbenzidine
(TMB) added into a blue product. This enzyme reaction was
stopped by dispensing an acidic solution (H2SO4) into the wells
after 10 min at room temperature turning the solution from
blue to yellow. The optical density (OD) of the solution at
450 nm was directly proportional to the amount of specific
antibodies bound. The standard curve was established by
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plotting the concentrations of the antibodies of the standards
(x-axis) and their corresponding OD values (y-axis) were
measured. The concentration of antibodies of the specimen
was directly read off the standard curve.
ANCA  The presence of ANCA was first screened by means
of a fixed neutrophil enzyme-linked immunosorbent assay
(ELISA). Methanol-fixed neutrophils were incubated with
control and coded sera at 1:100 dilutions. Neutrophil-bound
antibody was labeled by alkaline phosphatase-conjugated
goat antihuman IgG. After the addition of p-nitrophenol,
specific absorbance was measured at 405 nm. The cutoff for
positivity was determined by positive controls from well-
defined patients with UC. Indirect immunofluorescent staining
was then performed on ANCA ELISA-positive samples to
determine whether a predominantly perinuclear (pANCA)
or cytoplasmic (cANCA) staining pattern was present.
Methanol-fixed neutrophils on glass slides were incubated
with the coded sera samples (1:20 dilution). Specific binding
was visualized by fluorescence microscopy after the addition
of fluorescein-labeled antihuman IgG. The specificity of the
perinuclear staining pattern in UC was finally confirmed by
its disappearance after DNase treatment of the neutrophils.
Results were considered positive when both the ANCA titers
were above the cutoff and the indirect immunofluorescence
revealed a perinuclear binding of ANCA that disappeared
after DNase treatment.
Statistical analysis
The relations were concluded from the evidences with statistical
methods and summarized them in tables. Data was presented
as percentages or mean values ± standard deviation (SD). The
statistical package used in data interpretation (the two-tailed
Student’s t-test, Pierce regression coefficient assay) was Statistica
for Windows software (StatSoft, Inc., OK, U.S.A.).
RESULTS
Results are summarized in (Tables 1-3, Figures 1-4). Twenty-
seven patients with CD had only colonic localization (27/42),
terminal ileitis was in 7 cases (7/42). Both the small and large
bowels were affected in 8 cases (8/42). IgG type ASCA was
found in 9 patients (1 colitis, 4 ileitis, 4 duodenitis-ileitis-
colitis). IgA type ASCA was positive only in the patients with
terminal ileitis (6/10) and in the patients with the duodenitis-
ileitis-colitis type CD (10/15). The 27 patients with only
colonic localization (27/42) had no IgA type ASCA positivity
(Figures 1-2). All together, we detected that the increased
IgG and IgA type ASCA titers, were mainly in patients with
small bowel type CD (with the exception of one patient with
colitis-type form with only IgG type ASCA) and celiac disease
(Figure 3-4). IgG and IgA ASCA progressed together. IgA
type ASCA values were between 0.35-938.19 U/ml (positive
20 U/ml). The prevalence of ASCA in patients with celiac
disease outlined a possible role of anti-Saccharomyces
cerevisiae antibodies in GSE. These findings outlined a
noticeable startling resemblance, suggesting a possible kind
of connection between CD and GSE.
Table 1  ASCA positive patients in different diseases of
bowels
ASCA        ASCA        ASCA              IgG vs
  IgG+         IgA+       IgG+IgA+    IgA corr.(r)
All patients (n=68)       5            4 10         0.75
Crohn’s disease (n=42)       1            2   8         0.81
Ulcerative colitis (n=10)      2            1   0        -0.01
Celiac disease (n=16)       2            1   2         0.50
Controls (n=20)       0            0   0        -0.18
Notes: It is clear that there was no ASCA positivity in the
controls. ASCA positivity was common in patients with
Crohn’s disease. The ASCA IgG- and IgA-type seropositivity
was concomitant.
Table 2  ASCA positive patients with different forms of Crohn’s
disease
Affected section of the bowels         ASCA        ASCA       ASCA
          IgG+          IgA+        IgG+IgA+
Only the colon (n=27) 1      0             0
Large and small bowels both (n=8) 0      0             4
Only small bowels (n=7) 0      2             4
Small bowel together (n=15) 0      2             8
Notes: Both the IgA and IgG type ASCA associated to the small
bowels. P<0.0004, ASCA IgG+ vs small bowels; P<0.0001 ASCA
IgA+ vs small bowels.
Figure 1  ASCA IgG values in Crohn’s disease.
Table 3  Summary of ASCA positive cases with Crohn’s disease
Case: ASCA IgG ASCA IgA ASCA IgG+IgA Age (years) Sex Affected sections of gastrointestinal tract
1. + 19 Female Terminal ileum
2. + 46 Male Terminal ileum
3. + 37 Male Terminal ileum
4. + 38 Female Terminal ileum
5. + 50 Female Colon
6. + 29 Male From the duodenum to the rectum
7. + 40 Female Terminal ileum
8. + 24 Male Terminal ileum + colon
9. + 49 Female From the duodenum to the rectum
10. + 41 Female Terminal ileum
11. + 27 Male Terminal ileum + colon
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Figure 2  ASCA IgA values in Crohn’s disease.
Figure 3 ASCA IgG values in inflammatory diseases of
intestines.
Figure 4  ASCA IgA values in inflammatory diseases of
intestines. [The IgA type ASCA values are between 0.35-938.19
U/ml (positive: IgA 20 U/ml).]
DISCUSSION
Both celiac disease and Crohn’s disease are characterized by
the presence of distinct (auto) antibodies. Based upon our
results, theoretically and practically it is thinkable that ASCA
positivity is not only a specific marker of Crohn’s disease but
correlates with the (auto-) immune inflammation of the small
intestines How does it happen?
     Macrophages can produce proinflammatory cytokines (i.e.
TNF-a) with direct and indirect microbicide activity. Several
cell-wall components of Candida albicans were investigated
in relation with the TNF-alfa secretion of macrophages and
confirmed that they all had beta-1,2-oligomannoside[11,12].
The incubation with purified oligomannoside activated
macrophages and they secreted TNF-alfa (in dose and
molecule-size dependently) in vitro and in vivo[13,14]. Similar
observations were demonstrated with Saccharomyces cerevisiae:
the oligomannose structures influenced per interaction the
cytokine network[15-17]. It is conceivable that miscellaneous
fungus-ol igosaccharides ( their  signal  function in
phytopathology is well-known) could play a key role in the
regulation of human infections[18]. Oligomannosids of
Saccharomyces cerevisiae with modification by ASCA can
change their immunopathogenicity and trigger a process that
results in specific inflammation such as CD.
    The human gastrointestinal tract possesses a complex
ecosystem, the components of which are multifaceted and
metabolically diverse. Although the presence of intestinal
microflora certainly contributes to the maintenance of human
health, intestinal mucosa has the task, among others, of
preventing the passage of commensal microflora and
occasional pathogens to other compartments. To carry out such
a function, the mucosa has to behave as a physical barrier but
it also has to play an active role. Oral tolerance (OT) consists
of the oral administration of antigens that could alter the
response of the immune system[19]. This is a form of peripheral
immune tolerance in which mature lymphocytes in the
peripheral lymphoid tissues are rendered non functional or
hyporesponsive by prior oral administration of antigens. The
mechanisms by which OT is mediated include deletion or
anergy and active cellular suppression. The primary factor
determining which form of tolerance will be developed after
oral administration of antigen is its dosage. Thus, it is thought
that low doses of antigen can induce the generation of active
suppression, via regulatory T cells in the gut-associated
lymphoid tissue (GALT), which then migrate to the systemic
immune system. These regulatory T cells produce down-
regulatory cytokines such as IL-4, IL-10 and TGF-b in a Th2
/Th3 cytokine pattern. Conversely, high dose of antigen favors
anergy or clonal deletion. The phenomenon in which regulatory
cells, as generated by oral tolerance, are primed in an antigen
specific manner, but act in the respective microenvironment
in a non-antigen specific manner is called bystander
suppression. This phenomenon is of particular interest and can
explain the use of oral/mucosal tolerance in T cell mediated
autoimmune diseases such as rheumatoid arthritis and some
diseases in which the autoantigen remains unknown or where
there are reactivities to multiple autoantigens. T helper type 1
(Th1) lymphocytes secrete interleukin (IL)-2, interferon-g and
lymphotoxin-a, and stimulate type 1 immunity, which is
characterized by intense phagocytic activity. Conversely, Th2
cells secrete IL-4, IL-5, IL-9, IL-10 and IL-13, and stimulate
type 2 immunity, which is characterized by high antibody titers.
Type 1 and type 2 immunity are not strictly synonymous with
cell-mediated and humoral immunity, because Th1 cells also
stimulate moderate levels of antibody production, whereas Th2
cells actively suppress phagocytosis. For most infections caused
by large eukaryotic pathogens, type 1 immunity is protective,
whereas type 2 responses assist with the resolution of cell-mediated
inflammation. Severe systemic stress, immunosuppression, or
overwhelming microbial inoculation causes the immune system
to mount a type 2 response to an infection normally controlled
by type 1 immunity. Macrophages also play a crucial role in
the mucosal network as they must perform a number of diverse
cellular functions that allow them to kill invading micro-
organisms and neoplastic cells as well as produce growth
factors involved in wound healing. Macrophages that develop
these diverse functions arise from a common precursor. By a
process of selective adaptation, the common precursor monocyte/
macrophage differentiates into a distinctive macrophage with a
different and specific phenotype, characterized by the expression
of a specific set of gene products. The local environment plays
a critical role in shaping or directing the pattern or pathway of
macrophage differentiation: one pathway was believed to play
a role in wound repair and characterized by the induction of
insulin-like growth factor-1 (IGF-I) and a second pathway was
involved in macrophage cytocidal activation and characterized
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by the induction of the inducible form of nitric oxide synthase
(iNOS)[20,21].
     IBDs are a group of diseases due to chronic inflammation
of the gastrointestinal tract, but without proved etiology. IBD
appears to be resulted from a dysregulated immune response
with contributions from environmental, genetic, and bacterial
factors. In the last decades, our understanding of the
pathogenesis of IBD has greatly expanded but a better insight
is needed into the environmental agents responsible for either
initiation or perpetuation of IBD. The increasing attention given
to the ecosystem of the gut may help define the antigens
responsible for immune reactivity and provide opportunities
toward application of antigen-specific therapeutic
interventions such as induction of tolerance. Further
investigation into probiotic agents and their mechanisms is
especially appealing as a way to provide alternative therapies
to decrease the inflammatory response. Antibodies to an
oligomannose epitope of Saccharomyces cerevisiae
demonstrated in 60-70 % of the patients with Crohn’s disease.
The origin and clinicopathological role of ASCA have not
been clarified. The sporadic information about ASCA positivity
in patients suffering from gluten sensitive enteropathy in the
literature suggests another occurrence.
     We examined the ASCA’s occurrence in our patients and
compared it with the clinical picture of the Crohn’s disease.
The results supported the theory that ASCA positivity
correlated with small intestinal Crohn’s disease and in these
cases both IgG and IgA type antibodies were proved. The
relatively high incidence of ASCA in GSE was unexplained
but indicated further surveys to elucidate it as it was definitely
more than accidental[22]. The antibodies in the sera of the
analyzed ASCA positive cases proved a systemic immune
response against Saccharomyces cerevisiae and suggested the
end of the oral tolerance against the yeast’s antigens. The diet
restriction (elemental diet, total parenteral nutrition, and fecal
diversion) may ameliorate the status of the patients with
Crohn’s disease. It can also be speculated that the yeast-free
diet as a part of the therapy for the ASCA positive patients can
be reasonable, moreover the permanent “forbidding” of the
yeast can be an acceptable alternative in case of getting well.
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